Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

MRC WIMM Festive Decorating Competition 2024

Teams across the MRC WIMM decorated their labs and offices with tinsel, handmade decorations and repurposed lab materials, filling the Institute with festive cheer.

Davis Group receives Wellcome Discovery Award

Professor Simon Davis and Dr Mafalda Santos have won a 5-year award from the global charitable foundation Wellcome to fund a project titled “Small contacts, big decisions – early signal processing by T cells”. This has been awarded jointly with Professor Anna Lippert of the University of Würzburg.

Vaccines, Meteorites and Gene Editing at IF Oxford 2024

In October, members of the MRC Weatherall Institute of Molecular Medicine took part in a series of events for Oxford Science + Ideas Festival.

35 Years of the MRC WIMM

In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.

New biomarker and therapeutic target identified for blood cancers

Research from the MRC Molecular Haematology Unit has revealed a protein called galectin-1 as a key marker for disease progression and as a promising therapeutic target for patients with myeloproliferative neoplasms (a type of blood cancer).

Professor Ahmed awarded funding to create world’s first ovarian cancer prevention vaccine

Researchers at the MRC WIMM have been awarded up to £600,000 from Cancer Research UK (CRUK) to create the world’s first vaccine to prevent ovarian cancer.

The Oxford Omics Data Camp 2024: Spatial Transcriptomics

The MRC WIMM Centre for Computational Biology recently hosted the inaugural Oxford Omics Data Camp at Jesus College. The camp featured cutting-edge discussions, hands-on workshops and a two-day hackathon.

Researchers develop new tool to better predict AML outcomes in older patients

In a study published in the Journal of Clinical Oncology, an international research team has used machine learning to improve risk stratification for patients over 60 diagnosed with acute myeloid leukaemia, an aggressive type of blood cancer.

Senior Fellowship awarded to Beth Psaila

Congratulations to Beth Psaila, who has been awarded a Senior Fellowship funded by Cancer Research UK in partnership with Rosetrees Trust.

Of Mice and Men - Researchers demonstrate evolutionary conservation of blood stem cell subtypes

Researchers from the MRC Molecular Haematology Unit (MHU) have shown that blood stem cell subtypes found in mice also exist in humans. This provides important information for research into therapies to alleviate the negative effects of aging.

MRC WIMM Researchers at IF Oxford - book now

IF Oxford returns as a digital and in-real-life science and ideas Festival with events running throughout October 2024.

18 teams in the MRC WIMM receive LEAF Sustainability awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research laboratories to embed sustainability into their work.

Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies

Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.

Load More